{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:37Z","timestamp":1792481137224,"version":"4.5.0"},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej19-0140","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T22:09:13Z","timestamp":1559167753000},"page":"787-792","source":"Crossref","is-referenced-by-count":35,"title":["Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma"],"prefix":"10.1507","volume":"66","author":[{"given":"Yohei","family":"Koizumi","sequence":"first","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hirooka","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yukimoto","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuusuke","family":"Imai","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Miyake","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunzo","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Joko","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664\u2013671.","DOI":"10.1002\/ijc.23131"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, et al. (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 <i>via<\/i> inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459\u20135465.","DOI":"10.1158\/1078-0432.CCR-07-5270"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, et al. (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747.","DOI":"10.1155\/2014\/638747"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, et al. (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18.","DOI":"10.1186\/2045-824X-6-18"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, et al. (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512\u2013519.","DOI":"10.1007\/s00535-016-1263-4"},{"key":"6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"6 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. (2018) Lenvatinib <i>versus<\/i> sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163\u20131173.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, et al. (2011) Comparative effectiveness of axitinib <i>versus<\/i> sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931\u20131939.","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, et al. (2014) Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 32: 3391\u20133399.","DOI":"10.1200\/JCO.2013.54.5954"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584\u20133590.","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52\u201360.","DOI":"10.1055\/s-0030-1247132"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Bruix J, Sherman M; American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020\u20131022.","DOI":"10.1002\/hep.24199"},{"key":"12","unstructured":"12 National Cancer Institute, Division of Cancer Treated and Diagnosis Cancer Therapy Evaluation Program. Adverseevents\/CTCAE. Available at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed May 31, 2018."},{"key":"13","doi-asserted-by":"publisher","unstructured":"13 Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, et al. (2013) Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 23: 443\u2013448.","DOI":"10.1089\/thy.2012.0378"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, et al. (2013) Pazopanib <i>versus<\/i> sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722\u2013731.","DOI":"10.1056\/NEJMoa1303989"},{"key":"15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","volume":"21","author":"L van Doorn","year":"2011","unstructured":"15 van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, et al. (2011) Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21: 197\u2013202.","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Illouz F, Braun D, Briet C, Schweizer U, Rodien P (2014) Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 171: R91\u2013R99.","DOI":"10.1530\/EJE-14-0198"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ahmadieh H, Salti I (2013) Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int 2013: 725410.","DOI":"10.1155\/2013\/725410"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Matsuura B, et al. (2019) Destructive thyroiditis induced by lenvatinib in three patients with hepatocellular carcinoma. Intern Med 58: 791\u2013795.","DOI":"10.2169\/internalmedicine.1874-18"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, et al. (2010) Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57: 873\u2013880.","DOI":"10.1507\/endocrj.K10E-130"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Stevens DA, Harvey CB, Scott AJ, O\u2019Shea PJ, Barnard JC, et al. (2003) Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 17: 1751\u20131766.","DOI":"10.1210\/me.2003-0137"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Barnard JC, Williams AJ, Rabier B, Chassande O, Samarut J, et al. (2005) Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis. Endocrinology 146: 5568\u20135580.","DOI":"10.1210\/en.2005-0762"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 St Bernard R, Zheng L, Liu W, Winer D, Asa SL, et al. (2005) Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146: 1145\u20131153.","DOI":"10.1210\/en.2004-1134"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Szarama KB, Gavara N, Petralia RS, Chadwick RS, Kelley MW (2013) Thyroid hormone increases fibroblast growth factor receptor expression and disrupts cell mechanics in the developing organ of corti. BMC Dev Biol 13: 6.","DOI":"10.1186\/1471-213X-13-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15: 599\u2013616.","DOI":"10.1038\/s41571-018-0073-4"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/9\/66_EJ19-0140\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T03:53:45Z","timestamp":1569642825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/9\/66_EJ19-0140\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0140","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}